RNA Virus Infections
41
0
0
32
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
13 trials with published results (32%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
9.8%
4 terminated out of 41 trials
88.9%
+2.3% vs benchmark
20%
8 trials in Phase 3/4
41%
13 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (41)
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
Therapeutics for Moderate and Severe Dengue
Effectiveness of Ammonium Chloride in Reducing Viral Load
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
Clinic-based ART Diagnostic Evaluation
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19